Independent confirmation of the immunophenotypic ELN Scoring System in patients with MDS and CMML
Uta Oelschlaegel(University Hospital Carl Gustav Carus), Maximilian Alexander Röhnert(University Hospital Carl Gustav Carus), Jonas Schadt(University Hospital Carl Gustav Carus), Lisa Wagenführ(University Hospital Carl Gustav Carus), Leo Ruhnke(Krankenhaus Dresden-Friedrichstadt), Frank Kroschinsky(University Hospital Carl Gustav Carus), Katja Sockel(Innsbruck Medical University), Malte von Bonin(Städtisches Klinikum Dresden), Katharina Epp(University Hospital Carl Gustav Carus), Martin Bornhäuser(Technische Universität Dresden)
Cited by 0
Related Papers
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
|The Lancet Oncology|2015|402
Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
|Leukemia|2011|398
Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers
|Cancer Discovery|2021|282
Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection
|Bone Marrow Transplantation|1999|259